Clinical trials: sponsored by ANRS, Emerging Infectious Diseases
HIV, HIV Infections
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
Since the first line antiretroviral (ARV) treatment is now largely accessible in the Sub-Saharian Africa countries, documentation of virological failure, drug resistance patterns and second line treatment evaluation are still to…
- Trial name
- 2LADY (NCT00928187)
- Testing
- emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line), abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line), emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- Where
- 3 sites in Burkina Faso, Cameroon and 1 more
- Volunteers
- 454 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection
Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa
Thilao is a multi-country, phase 2b, non-randomized study, in Burkina Faso, Cote d'Ivoire, Mali and Senegal, West Africa. HIV-1 adults with 2nd-line ART virologic failure (plasma HIV-1 RNA >1000 copies/ml) will be recruited and…
- Trial name
- THILAO (NCT02025868)
- Testing
- adherence reinforcement, Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 2 more
- Volunteers
- 201 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin
The purpose fo the study is to evaluate the efficacy defined by the sustained virological response (SVR), in patients with compensated cirrhosis treated with PEG-IFN, RBV and telaprevir or boceprevir in the French Early Access…
- Trial name
- CUPIC (NCT01514890)
- Where
- France
- Volunteers
- 675 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon
Infections with HIV-1 group O are found in 1 to 3 % of persons living with HIV in Cameroon. The natural history and treatment response is not well understood.
- Trial name
- NCT00658346
- Testing
- Treatment initiation for HIV-1 group O infected patients, Treatment initiation for HIV-1 group M infected patients
- Where
- 2 sites in Cameroon
- Volunteers
- 141 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C
PoC-HCV Genedrive Viral Detection Assay Validation Study
The principal objective is to assess the diagnostic accuracy of the PoC assay (Genedrive, Epistem) to detect HCV RNA against the reference standard of commercial real-time polymerase chain reaction (RT-PCR) assay (RealTime HCV…
- Trial name
- NCT02992184
- Testing
- HCV RNA detection with Genedrive assay, HCV RNA detection with RealTime HCV
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV
National Evaluation of PI-based 2nd Line Efficacy in Cambodia
Medium and long term efficacy of PI-based 2nd line antiretroviral (ARV) therapy in Cambodia is poorly documented when the numbers of patients on treatment and their duration are increasing.
- Trial name
- NCT01801618
- Where
- 13 sites in Cambodia
- Volunteers
- 15,001,351 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients
The bacterial diversity of HIV patients digestive microbiota seropositive is poorly understood, it remains to be defined.
- Trial name
- MICROGUT (NCT02116374)
- Testing
- Physiopathology study
- Where
- 4 sites in France
- Volunteers
- 80 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, HIV-uninfected Children
A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)
This study aims to perform a comprehensive neuro-cognitive evaluation of the 4-7 year old children from the Pediacam cohort (ANRS 12140 /12225, NCT02043418).
- Conditions
- HIV, HIV-uninfected Children, Children Exposed to HIV
- Trial name
- PediacamDEV (NCT02570334)
- Testing
- HIV-infected children initiated antiretroviral treatment within the first 7 months of life
- Where
- 3 sites in Cameroon
- Volunteers
- 400 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infection, Liver Injuries
Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients
This study will allow to assess liver related injuries in HIV patients.
- Trial name
- ANRS ECHAM (NCT02093754)
- Testing
- MRI and biopsy
- Where
- 7 sites in Belgium, France and 1 more
- Volunteers
- 460 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection, AIDS
Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients
The objective of the OPTIMAL study is to demonstrate that the adjunction of Maraviroc to a combination of antiretroviral therapy in naive and late diagnosed HIV-1 infected patients counts may accelerate the kinetics of immune…
- Trial name
- OPTIMAL (NCT01348308)
- Testing
- Maraviroc (Celsentri)
- Where
- France
- Volunteers
- 407 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age
The MONOD trial aim to evaluate the implementation of early antiretroviral treatment strategies in HIV-infected infants and assess the feasibility and efficacy of simplifying the initial proposed regimen after a successful one…
- Trial name
- NCT01127204
- Testing
- AZT-3TC-LPV/r twice a day, ABC-3TC-EFV once a day
- Where
- 4 sites in Burkina Faso, Côte d’Ivoire
- Volunteers
- 161 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV, Reproductive Health
Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa
According to the recent World Report on Disability, around 15% of the world population lives with a disability and 80% of people with disabilities (PWD) live in developing countries.
- Conditions
- HIV, Reproductive Health, Disability
- Trial name
- HandiVIH (NCT02192658)
- Where
- Cameroon
- Volunteers
- 1,610 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Cryptococcal Meningitis, HIV
Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa
The aim of the trial is to demonstrate that in a sub-Saharan African setting, the association of: 1. Oral treatment : high dose of fluconazole (1600mg/d) associated with flucytosine (100 mg/kg/j) as induction therapy 2.
- Trial name
- Flucocrypto (NCT01715922)
- Testing
- Fluconazole, Flucytosine, lumbar punctures
- Where
- 7 sites in Burundi, Côte d’Ivoire
- Volunteers
- 41 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hiv Infection
Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients
Protocol date and version RCB Id : 2013-A00547-38 Etude ANRS EP 52 PIECVIH Title of Study: EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS Short title - PIECVIH study Sponsor French National Institute for…
- Trial name
- ANRS EP 52 (NCT01899196)
- Testing
- blood sampling,
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1
Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent
The advent of highly active antiretroviral treatment has resulted in the survival into adolescence of an increasing proportion of infants and children with perinatal HIV infection in Senegal.
- Trial name
- NCT01771562
- Where
- 2 sites in Senegal
- Volunteers
- 330 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV Recurrence, Liver Transplantation
Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection
The purpose of this study is to evaluate the efficacy, safety and tolerability of direct-acting antivirals therapy in liver transplanted patients who experienced HCV recurrence.
- Conditions
- HCV Recurrence, Liver Transplantation, Direct-acting Antiviral Agents
- Trial name
- ANRSCO23CUPILT (NCT01944527)
- Where
- France
- Volunteers
- 699 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C Virus Genotype 4 Infection
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
ANRS HC 33 is a pilot study to assess efficacy and safety of a DCV 3DAA therapy with Asunaprevir, Daclatasvir and BMS-791325 in HCV genotype 4-infected patients after failure of pegylated Interferon-Ribavirin regimen.
- Trial name
- QUATTROTURBO (NCT02309450)
- Testing
- .Asunaprevir, Daclatasvir and BMS - 791325
- Where
- France
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Evaluate after 48 weeks, the capacity of a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment, in HIV-1 treated patients with undetectable viral load for at least 12 months and continuous…
- Trial name
- ANRS162-4D (NCT02157311)
- Testing
- Four consecutive days on treatment and 3 days off
- Where
- 17 sites in France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Tuberculosis, HIV
Evaluation of an Innovative Tuberculosis Diagnostic Test
Diagnosis of tuberculosis (TB)in young children is a challenge due to atypical non-specific symptoms, difficulty to expectorate mucus, paucibacillary nature of pulmonary TB and low sensitivity of available diagnostic tools.
- Trial name
- PROMISE-TB (NCT02573623)
- Where
- Zambia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1 Infection, Treatment Resistant Disorders
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Management of participants with low-level persistent viremia
- Conditions
- HIV-1 Infection, Treatment Resistant Disorders, Viremia
- Trial name
- NCT02247687
- Testing
- Protease inhibitor, Isentress® (raltegravir), Counseling arm
- Where
- 20 sites in France
- Volunteers
- 4 people
- Sponsor
- ANRS, Emerging Infectious Diseases